Browse molecules
Download our free molecule poster today. Choose a format for print or for digital use.
Download our free molecule poster today. Choose a format for print or for digital use.
Doramapimod (BIRB 796) is a potent inhibitor of the p38 mitogen activated protein kinase (MAPK). The compound shows anti-inflammatory properties at nanomolar concentrations in cell cultures, which are based on the suppression of TNF-a production.
We share the highly potent and selective SOS1:: KRAS inhibitor BI-3406. The small molecule inhibitor binds to the catalytic site of SOS1, inhibiting the interaction with RAS‐GDP. This significantly reduces formation of GTP-loaded KRAS, thereby inhibiting downstream MAPK signaling.
BI-8668 is a potent and well-characterized epithelial sodium channel (ENaC) inhibitor, for in vitro and in vivo use, structurally distinct from amiloride derived ENaC inhibitors.
S-Bepafant is the active enantiomer of the racemic PAFR antagonist Bepafant. S-Bepafant shows slightly enhanced potency in vivo compared to racemic Bepafant, and both are significantly more active than Apafant.
Bepafant is a synthetic racemic PAFR antagonist based on the hetrazepine scaffold. It is a pharmacologically more potent derivative of Apafant.